Grab Holdings Ltd. vs Zoetis Inc — how do they compare? Grab Holdings Ltd. trades at $3.72 (market cap $15.62B), while Zoetis Inc trades at $77.37 (market cap $31.25B). The key difference: Zoetis Inc is far larger — about 2× Grab Holdings Ltd.'s market cap, and Zoetis Inc pays a 2.84% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals.
| GRAB | ZTS | |
|---|---|---|
Market Cap | $15.62B | $31.25B |
Sector | Technology | Health |
52-Week High | $6.45 | $156.76 |
52-Week Low | $3.27 | $71.91 |
Enterprise Value | $11.32B | $38.54B |
Dividend Yield | — | 2.84% |
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.715, down 2.24% today, with a bullish technical signal from moving averages. The company achieved profitability in 2025 with $268M net income and 7.95% margin, showing significant improvement from previous losses. Revenue grew to $3.37B in 2025, with strong analyst consensus of 11 buys versus 1 sell. Recent news includes CEO share sales and Uber CEO's board departure, creating some investor uncertainty despite positive earnings beats.
GRAB presents a compelling turnaround story with recent profitability and strong growth prospects in Southeast Asian markets. The stock trades at a discount to the $5.45 consensus target, offering 47% upside potential. Key risks include competitive pressures, execution challenges in expanding financial services, and insider selling activity. The company's improving cash flow and debt management support the bullish analyst outlook.
Zoetis (ZTS) trades at $77.13, up 4.12% in the last session, with a bearish technical signal from moving averages. The company reported strong 2025 results, including $9.47B revenue and $2.67B net income, with high profitability margins. Recent news highlights a securities class action lawsuit and the launch of Lenivia in Canada and the EU. Cash flow improved to a positive $325M in 2025, though net cash flow is projected to decline in 2026.
The stock presents a mixed outlook: strong fundamentals and a consensus price target of $101.43 suggest upside, but legal risks and bearish technicals pose near-term headwinds. Earnings momentum is key, with Q2 2026 results critical after a Q1 miss. Institutional sentiment is cautious despite no sell ratings.
Trailing returns across standard periods
Latest headlines on both assets
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →